Recall events
/
Event 84336
Event summary
Timeline bucket November 20, 2019
Product types Drug
Classifications Class I
Statuses Terminated
Recalling firm wording AuroMedics Pharma LLC
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
2 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 2
Mirtazapine Tablets, USP, 15 mg, 500-count tablets, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810 NDC 13107-031-05
D-0636-2020
Recall number D-0636-2020
Initiated November 20, 2019
Classification Class I
Status Terminated
Quantity N/A
App-derived interpretation
Labeling or packaging
reason.labeling_packaging · v1.0.0
Labeling: Label Error
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets.
Code information Lot #: 03119002A3, Exp 3/2022
Distribution pattern Nationwide
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[15097]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 2
Mirtazapine Tablets, USP, 7.5 mg, 500-count tablets, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810 NDC 13107-001-05
D-0637-2020
Recall number D-0637-2020
Initiated November 20, 2019
Classification Class I
Status Terminated
Quantity N/A
App-derived interpretation
Labeling or packaging
reason.labeling_packaging · v1.0.0
Labeling: Label Error
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets.
Code information Lot #: 03119002A3, Exp 3/2022
Distribution pattern Nationwide
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[15893]
FDA event record
· Exact recall-number query on openFDA